Cue Health Inc. (HLTH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cue Health Inc. (HLTH) trades at $0.04. Cue Health Inc. develops and commercializes diagnostic platforms for various healthcare needs. Market cap: $6.90M, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for HLTH: HLTH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HLTH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HLTH: 1/1 perspectives are bearish.
Cue Health Inc. (HLTH) Healthcare & Pipeline Overview
Cue Health Inc. is a healthcare technology company focused on developing and marketing its Cue Integrated Care platform, which offers rapid, point-of-care diagnostic testing solutions. The platform targets individuals, enterprises, healthcare providers, and public health agencies, positioning it within the evolving landscape of decentralized diagnostics.
What Is the Investment Thesis for HLTH?
Cue Health Inc. presents a high-risk, high-reward investment opportunity within the point-of-care diagnostics market. The company's Cue Integrated Care platform offers a potentially disruptive solution for rapid and accurate testing. However, with a market capitalization of $0.01 billion, a negative profit margin of -581.5%, and a negative gross margin of -97.9%, the company faces significant financial challenges. Future growth hinges on expanding the test menu beyond COVID-19, securing regulatory approvals for new tests, and achieving wider market adoption. The company's beta of 1.09 suggests its stock price is as volatile as the market. Investors should carefully consider the company's financial position, competitive landscape, and execution risks before investing. The company's success depends on its ability to innovate, commercialize new diagnostic tests, and achieve profitability.
Based on FMP financials and quantitative analysis
HLTH Key Highlights
- Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
- Negative profit margin of -581.5% reflects substantial losses and the need for improved cost management and revenue generation.
- Negative gross margin of -97.9% suggests that the cost of goods sold exceeds revenue, indicating unsustainable pricing or high production costs.
- Beta of 1.09 indicates that the stock is slightly more volatile than the overall market.
- The company operates in the rapidly evolving point-of-care diagnostics market, driven by demand for faster and more convenient testing solutions.
Who Are HLTH's Competitors?
Who Are HLTH's Competitors?
HLTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| KA Kineta, Inc. | $0.57 | -30.77% | 8M | 45 |
| LCI Lannett Company, Inc. | $0.69 | +9.02% | $7.38M | 39 |
| HNGE Hinge Health, Inc. | $54.50 | +1.15% | 5B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.00 | +0.00% | $20.00M | 67 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| FOXO FOXO Technologies Inc. | $0.00 | +0.00% | 3K | 63 |
| NH NantHealth, Inc. | $1.35 | +0.00% | 52 | |
| DOCS Doximity, Inc. | $21.40 | +1.57% | $4.00B | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HLTH's Key Strengths?
- Integrated platform with hardware and software components.
- Rapid and accurate diagnostic results at the point of care.
- Data and analytics capabilities for healthcare providers and patients.
- Existing COVID-19 testing kits provide a foundation for future growth.
What Are HLTH's Weaknesses?
- Negative profit and gross margins indicate financial instability.
- Limited test menu beyond COVID-19.
- Dependence on regulatory approvals for new tests.
- Intense competition in the point-of-care diagnostics market.
What Could Drive HLTH Stock Higher?
- Potential FDA approval for new diagnostic tests on the Cue platform, expanding its clinical utility.
- Expansion of strategic partnerships with healthcare providers and payers to increase market access.
- Continued development and commercialization of new features and capabilities for the Cue Integrated Care platform.
What Are the Key Risks for HLTH?
- Regulatory hurdles and delays in obtaining approvals for new tests.
- Intense competition from established players in the diagnostics market.
- Financial instability due to negative profit and gross margins.
- Changes in healthcare policies and reimbursement rates affecting the adoption of point-of-care diagnostics.
What Are the Growth Opportunities for HLTH?
- Expansion of Test Menu: Cue Health has the opportunity to expand its test menu beyond COVID-19 to include other infectious diseases, women's health, and chronic conditions. The market for point-of-care diagnostics is projected to reach $43.7 billion by 2027, offering a significant opportunity for Cue Health to increase its revenue and market share. Success depends on the company's ability to develop and validate new tests, obtain regulatory approvals, and integrate them into its existing platform. Timeline: Ongoing.
- Strategic Partnerships: Cue Health can pursue strategic partnerships with healthcare providers, payers, and pharmaceutical companies to expand its market reach and accelerate adoption of its platform. Collaborations with large healthcare systems could provide access to a broader patient base and facilitate integration into existing clinical workflows. The potential impact of these partnerships is significant, as they can drive revenue growth and enhance the company's credibility. Timeline: Ongoing.
- Geographic Expansion: Cue Health can expand its geographic presence beyond the United States to target international markets with unmet diagnostic needs. Emerging markets, in particular, offer significant growth opportunities due to increasing healthcare spending and limited access to traditional laboratory testing. Successful geographic expansion requires adapting the company's platform to local regulatory requirements and establishing distribution networks. Timeline: 2027-2030.
- Direct-to-Consumer Marketing: Cue Health can leverage direct-to-consumer marketing strategies to increase awareness and adoption of its platform among individuals seeking convenient and accessible diagnostic testing. This includes online advertising, social media campaigns, and partnerships with telehealth providers. The direct-to-consumer market for diagnostics is growing rapidly, driven by increasing consumer awareness and demand for personalized healthcare solutions. Timeline: Ongoing.
- Integration with Telehealth Platforms: Cue Health can integrate its platform with telehealth platforms to provide remote patient monitoring and virtual care services. This integration would enable healthcare providers to remotely monitor patients' health status, diagnose conditions, and prescribe treatments. The telehealth market is experiencing rapid growth, driven by increasing adoption of virtual care and remote monitoring technologies. The global telehealth market is projected to reach $55.6 billion by 2027. Timeline: 2027-2028.
What Opportunities Does HLTH Have?
- Expansion of test menu to include other infectious diseases and chronic conditions.
- Strategic partnerships with healthcare providers, payers, and pharmaceutical companies.
- Geographic expansion to international markets.
- Integration with telehealth platforms for remote patient monitoring.
What Threats Does HLTH Face?
- Competition from established players in the diagnostics market.
- Regulatory hurdles and delays in obtaining approvals for new tests.
- Changes in healthcare policies and reimbursement rates.
- Potential for technological obsolescence.
What Are HLTH's Competitive Advantages?
- Proprietary Technology: The Cue Integrated Care platform is based on proprietary technology, providing a competitive advantage.
- Integrated System: The integrated hardware and software components of the Cue platform create a seamless user experience.
- Rapid and Accurate Results: The Cue platform delivers rapid and accurate diagnostic results at the point of care.
- Data and Analytics Capabilities: The Cue Data and Innovation Layer provides valuable insights for healthcare providers and patients.
What Does HLTH Do?
Cue Health Inc., established in 2010 and headquartered in San Diego, California, is a healthcare technology company dedicated to designing and developing a diagnostic platform for a range of diagnostic tests. The company's core offering is the Cue Integrated Care platform, a comprehensive system comprising both hardware and software components. This platform includes the Cue Health Monitoring System, which features the Cue Reader (a portable, reusable reader), the Cue Cartridge (a single-use test cartridge), and the Cue Wand (a sample collection wand). The Cue Data and Innovation Layer provides cloud-based data and analytics capabilities, while Cue Virtual Care Delivery Apps, including the Cue Health App and Cue Enterprise Dashboard, facilitate virtual care delivery. The company also offers Cue Ecosystem Integrations and Apps, enabling integration with third-party applications and sensors. Initially, Cue Health gained prominence through its COVID-19 testing kits designed for use with the Cue Health Monitoring System. These kits provided rapid, on-site testing capabilities, addressing a critical need during the pandemic. The company's focus extends beyond COVID-19, with plans to expand its platform to detect a variety of other infectious diseases and health conditions. Prior to December 2017, the company was known as Cue Inc.
What Products and Services Does HLTH Offer?
- Designs and develops a diagnostic platform for various diagnostic tests.
- Offers the Cue Integrated Care platform, comprising hardware and software components.
- Provides the Cue Health Monitoring System, including the Cue Reader, Cue Cartridge, and Cue Wand.
- Offers the Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability.
- Provides Cue Virtual Care Delivery Apps, including Cue Health App and Cue Enterprise Dashboard.
- Offers Cue Ecosystem Integrations and Apps, allowing integrations with third-party applications and sensors.
- Provides COVID-19 testing kits for the Cue Health Monitoring System.
How Does HLTH Make Money?
- Sells the Cue Health Monitoring System, including the Cue Reader and Cue Cartridges.
- Generates revenue from the sale of COVID-19 testing kits.
- Offers data and analytics services through the Cue Data and Innovation Layer.
- Provides virtual care delivery applications through the Cue Health App and Cue Enterprise Dashboard.
What Industry Does HLTH Operate In?
Cue Health Inc. operates within the medical and healthcare information services industry, a sector experiencing rapid growth due to technological advancements and increasing demand for point-of-care diagnostics. The market is characterized by intense competition, with established players like Laboratory Corporation of America (LCI) and emerging companies vying for market share. The industry is driven by trends such as personalized medicine, remote patient monitoring, and the need for rapid and accurate diagnostic testing. Cue Health's success depends on its ability to differentiate its platform, secure regulatory approvals, and establish strategic partnerships within this competitive landscape.
Who Are HLTH's Key Customers?
- Individuals seeking convenient and accessible diagnostic testing.
- Enterprises looking to provide on-site testing for employees.
- Healthcare providers needing rapid and accurate diagnostic information.
- Payors seeking to improve patient outcomes and reduce healthcare costs.
- Public health agencies requiring rapid disease surveillance and response capabilities.
HLTH Financials
HLTH Latest News
-
Earnings Scheduled For May 10, 2023
benzinga · May 10, 2023
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · May 4, 2023
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Apr 17, 2023
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Dec 22, 2022
HLTH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HLTH.
Price Targets
Wall Street price target analysis for HLTH.
HLTH MoonshotScore
What does this score mean?
The MoonshotScore rates HLTH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Who Are HLTH's Competitors?
Leadership: Clint Sever
CEO
Clint Sever serves as the CEO of Cue Health Inc. His background includes experience in technology and healthcare, with a focus on developing and commercializing innovative diagnostic solutions. He has been instrumental in guiding Cue Health through its growth phase, including the development and launch of the Cue Integrated Care platform. His expertise spans product development, regulatory affairs, and market strategy.
Track Record: Under Clint Sever's leadership, Cue Health has secured FDA authorization for its COVID-19 test and expanded its platform to address other diagnostic needs. He has overseen the company's growth in revenue and market presence, as well as its efforts to establish strategic partnerships with healthcare providers and payers. Key milestones include the commercialization of the Cue Health Monitoring System and the development of the Cue Data and Innovation Layer.
Common Questions About HLTH (Healthcare)
What does Cue Health Inc. do?
Cue Health Inc. is a healthcare technology company focused on developing and commercializing its Cue Integrated Care platform. This platform provides rapid, point-of-care diagnostic testing solutions for individuals, enterprises, healthcare providers, and public health agencies. The Cue platform consists of a portable reader, single-use test cartridges, and a cloud-based data and analytics system. The company's initial focus was on COVID-19 testing, but it plans to expand its test menu to include other infectious diseases and health conditions.
What do analysts say about HLTH stock?
AI analysis is currently pending for HLTH. Without this analysis, a summary of analyst consensus, key valuation metrics, and growth considerations cannot be provided. Investors should consult with financial professionals and conduct their own due diligence before making any investment decisions. The company's financial performance, competitive landscape, and regulatory environment should be carefully considered.
What are the main risks for HLTH?
Cue Health Inc. faces several key risks, including intense competition in the point-of-care diagnostics market, regulatory hurdles and delays in obtaining approvals for new tests, and financial instability due to negative profit and gross margins. The company's success depends on its ability to innovate, commercialize new diagnostic tests, and achieve profitability. Changes in healthcare policies and reimbursement rates could also affect the adoption of its platform. Investors should carefully consider these risks before investing in HLTH.
What are the key factors to evaluate for HLTH?
Evaluating HLTH involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Integrated platform with hardware and software components. Primary risk to monitor: Regulatory hurdles and delays in obtaining approvals for new tests. This is not financial advice.
How frequently does HLTH data refresh on this page?
HLTH prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HLTH's recent stock price performance?
Recent price movement in Cue Health Inc. (HLTH) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Integrated platform with hardware and software components. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HLTH overvalued or undervalued right now?
Determining whether Cue Health Inc. (HLTH) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HLTH?
Before investing in Cue Health Inc. (HLTH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- The analysis is based on publicly available information and management commentary.
- Future performance is subject to various risks and uncertainties.